New device for delivering therapeutics in situ in cancer treatment

OUEST VALORISATION



12 Juillet 2019

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

L'innovation


Context: Despite their efficiency, chemotherapy treatments are being challenged by physicians regarding their strong side-effects when they are administrated in systemic way. Numerous devices have been designed to deliver the treatment in situ hence reducing side-effects.

Issue: Due to implantation’s site (inside the vessels for some), their design or the lack of delivery management, they cause other side effects including thrombosis or surgery complication. So there is still a need to develop a device which is able to deliver in situ the treatment and prevent cancer relapse.

Solution: Thank to its expertise in both microfluidic and biological field, the research team has developed a new implantable medical device which could be used to deliver therapeutics directly inside the tumor or around it while avoiding surgery complication and reducing side-effects eventually.


Ses bénéfices
Dose delivery control
To be used with different kind of molecules (cytotoxic agent, siRNA, Protein or antibody)
Less side-effect expected
Easy to manage the dose escalation by chronic or intermittent injections

Ses applications
Glioblastoma after resection to enhance Stupp protocole
Hepato-carcinoma and metastasis in late stage and in first or second line treatment for non-resecable tumor

Stade de développement
TRL3 - Recherche de la preuve de concept

Laboratoire de recherche
UMR_S 1066 - MINT

Équipe de recherche
Conception de Micro et Nanomédecines

Propriété intellectuelle associée
FR : FR1656954 - filed on the 07-21-2016
WO - CA,CN,EP,JP,US

Download the offer Download the offer

Newsletter